Documentos de Académico
Documentos de Profesional
Documentos de Cultura
ENFERMEDAD OLIGOMETASTSICA.
Tpicos
Definicin
de Oligometstasis.
Comportamiento
SBRT
biolgico y molecular.
Desarrollo
tecnolgico de radioterapia.
Resultados
Masculino 47 aos de edad, recibi post prostatectomia rad por ACAP de Alto
Riesgo y lucrin. No acepto RT adyuvante. Cursa con PSA 15 y metstasis
seas #2 (hueso ilaco y sacra S1) PET CT Ch ms ganglio ilaco derecho.
Oligometstasis y Oligorecurrencia
USE
Estado Estable:
No 5
lesiones
de 5
cm.
http://sciencelife.uchospitals.edu/2015/02/03/gene-blocking-clusters-of-micrornas-can-limit-the-spread-of-cancer
SBRT
Tratamiento Convencional
hipofraccinado paliativo es limitado.
Radioterapia
Metstasis
fx,
Metstasis
Limitado
Re
irradiacin limitada.
Usualmente
Es
Radioterapia Externa.
Uso
Tiempo
Hipofraccionamiento
Dosimetra
1400
1200
1000
800
600
400
200
0
#Papers
QA
Muy
meticuloso
Por Fsica
Mdica.
Activacin de mecanismo no
presente en RT convencional.
Postow, MA, Callahan, MK, Barker, CA, Yamada, Y, Yuan, J, Kitano, S, Mu, Z, Rasalan, T, Adamow, M, Ritter, E, Sedrak, C,
Jungbluth, AA, Chua, R, Yang, AS, Roman, RA, Rosner, S, Benson, B, Allison, JP, Lesokhin, AM, Gnjatic, S & Wolchok, JD 2012, 'Immunologic correlates of the
abscopal effect in a patient with melanoma' New England Journal of Medicine, vol 366, no. 10, pp. 925-931
SBRT en Oligometstasis
Lesiones/pte
s
Dosis
Resultados
Bloomberg et al
14/10
7.7-45Gy/1-4 fx
92% CL
Uematsu et al
43/22
33-71Gy/ 5-15 fx
98% CL
Nagata et al
9/9
48Gy/ 4 fx
67% CL
Norishisa et al
43/34
48-60Gy/ 4-5 fx
Autor
Ptes/Lesione
s
Dosis
Resultados
Rusthoven et al
38/63
48-60Gy/ 3 fx
1998: BLOMGREN ET AL, REPORT STUDIO PILOTO USANDO 20-40GY (1-2 FX) PARA UN PTV PERIFRICO
ALCANZANDO 95% CL
Prospectiva
Autor
Ptes/Lesione
s
Dosis
Resultados
Herfarth et al
56/33
14-26Gy/fx
78% CL
Kavanagh et al
28/21
12-20Gy/ 3 fx
93% CL
Mndez Romero et
al
34/14
37.5Gy/ 3fx
94% CL
Rusthoven et al
63/57
36-60Gy/ 3 fx
Niibe et al, 1/7 falla en met. sea solitaria con dosis 40-50Gy en 20-25 fx (DBE10; 48Gy).
Milano et al, #85/ 40 ptes, SBRT, 76% & 59% SVG a 2 & 4 @.
SBRT A HUESO QUIZS PUEDE OFRECER MEJORAR SOBREVIDA EN CASOS OLIGOREC POR CA DE
MAMA.
Niibe et al. Anticancer Res . 2008.
Milano et al. Breast Cancer Res Treat. 2009.
Reportes de pobre SVG corto plazo con RT c/s QT con RT convencional e hiperfx:
Hong et al: 34% (5@) ; Kim et al: 19% (60.Gy/ 3@); Niibe et al: 31% (5@).
ww.intechopen.com/books/frontiers-in-radiation-oncology/curative-radiotherapy-in-metastatic-disease-how-to-develop-the-role-of-radiotherapy-from-local-to-me
26
Consolidacin post
respuesta o estable post
sistmica
30
Nuevas metstasis
(previa sistmica)
19
Caractersticas:
*Mama (32%), CRC (26%)
*Adenoca (74%)
*Sitio Pulmn (41%), Hgado (45%)
la ESO-MBC Task Force da su original recomendacin: una pequea pero muy importante
subunidad de ptes metastsicas, pe. Aquellas con un tumor solitario pueden alcanzar la
remisin completa y prolongar su sobrevida.
Ca de Mama rojo
No Ca de Mama azul
PROTOCOLO
DE ESTUDIO
Patrones de Recurrencia
Sobrevida estimada.
INTRODUCTION
We report here our first experience on using Volumetric Modulated Arc Therapy
(VMAT) "RapidArc" and present dosimetric results in terms of conformity index (CI)
and homogeneity index (HI). A moderated Hypofractionated Stereotactic Body
Radiotherapy (Hypo-SBRT) was applied in all cases using Cone Beam CT (CBCT) for
patient positioning. This is the first experience in this kind of radiotherapy treatment in
the Republic of Panama.
METHOD
Four patients with five metastatic extra cranial lesions in different anatomic sites
were retrospectively reviewed. VMAT plans, with one or two arcs, were optimized to
deliver the treatment dose to the 95% of the Planning Target Volume (PTV) and
applying suitable constrains to the organs at risk (OAR) involved. In some cases
magnetic resonance or positron emission tomography images were fused to the
planning CT and used for delineation guidance. Planning Tumor Volume (PTV) size
(in cm3) and the volume covered by the 95% of the treatment isodose curve were
evaluated to determine the over or under coverage of the PTV with respect to OARs
(CI). The values of D2%, D98% and D50% were obtained from the Dose Volume
Histograms (DVH) and were used to calculate the HI. All calculated plans were verified
by relative and absolute dose measurements previous to delivery. Patients were
positioned for treatment under CBCT image guidance in all treatment sessions.
Prescribed
PTV volume dose PTV
3
Case*
(cm )
(Gy)
Fractions
Planning
mean dose
(Gy)
PTV mean
dose plan
(%)
D2%-D98%
(Gy)
95%CI
HI
66.6
25
26.57
105.7
3.32
1.15
0.12
8.1
50
10
52.34
104.1
7.88
1.29
0.15
5.1
30
31.98
105.1
4.5
0.99
0.14
40.6
27.5
29.91
106.3
4.85
0.94
0.16
126.3
19.5
20.49
104.5
2.29
1.32
0.11
* Sites: 1: Sacrum bone; 2: Single Liver Mets; 3: L5 bone; 4: Central Lung Mets; 5: L4/L5 bone.
RESULTS
Five metastatic (from three colorectal and two prostate carcinomas) lesions were
treated. They were located at the sacrum bone (one case) , vertebral bones in the
lumbar region (2 cases), the liver (one case) and the central lung parenchyma (one
case). One patient was treated in two oligometastatic sites, the lumbar spine and the
liver. The lung colorectal metastasis was a re-irradiation. The ECOG performance
status was between 0-1. PTV mean size was 49.34 cm 3 (range: 5.1-126.3 cm3). PTV
mean prescribed dose was 30.4 Gy (range: 19.5-50 Gy) with a mean dose per fraction
of 5.6 Gy (range: 5-6.5 Gy) and a mean of 5.6 sessions (range: 3-10) per treatment.
Table 1 shows the results of the CI and HI indexes.
Figure 1. Dose distributions corresponding to the SBRT plan of (a) central lung
metastases (b) a single liver lesion.
CONCLUSIONS
Hypo-SBRT using VMAT exhibited a good PTV coverage with an acceptable 95% CI
and HI indexes. The results obtained in this initial experience with SBRT treatments
are considered satisfactory.
Conclusiones
SBRT en Oligomets/recurrencias
Es
Una
Falta
Tener
Terapia
GRACIAS
tp://www.intechopen.com/books/frontiers-in-radiation-oncology/curative-radiotherapy-in-metastatic-disease-how-to-develop-the-role-of-radiotherapy-from-local-to-me